TamoxifenAntineoplastic Agents, HormonalAromatase InhibitorsChemotherapy, AdjuvantBreast NeoplasmsNitrilesTriazolesPostmenopauseReceptors, EstrogenNeoplasms, Hormone-DependentAdjuvants, ImmunologicPremenopauseEndocrine GlandsEndocrine SystemGoserelinEstrogen AntagonistsDisease-Free SurvivalReceptors, ProgesteroneSurvivalEndocrine Gland NeoplasmsTreatment OutcomeEndocrine System DiseasesEndocrine DisruptorsFreund's AdjuvantPrognosisNeoplasm Recurrence, LocalSelective Estrogen Receptor ModulatorsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyNeoplasm StagingEstrogen Receptor ModulatorsRandomized Controlled Trials as TopicFollow-Up StudiesRadiotherapy, AdjuvantAdjuvants, PharmaceuticToremifeneMultiple Endocrine Neoplasia Type 1EstradiolMultiple Endocrine NeoplasiaRaloxifeneCytochrome P-450 CYP2D6Estrogen Receptor alphaEstrogensDrug Resistance, NeoplasmMultiple Endocrine Neoplasia Type 2aFluorouracilSurvival AnalysisAminoglutethimideAluminum HydroxideEndometrial NeoplasmsTime FactorsAntineoplastic AgentsLymphatic MetastasisCyclophosphamidePancreasMenopauseEnteroendocrine CellsImmunohistochemistrySurvival RateHormonesMultiple Endocrine Neoplasia Type 2bMastectomyImmunizationIslets of LangerhansReceptor, erbB-2OvariectomyMice, Inbred BALB CDrug Administration ScheduleClinical Trials as TopicMethotrexateDose-Response Relationship, DrugCell Line, TumorUterusRetrospective StudiesPancreatic NeoplasmsEndocrinologyAmenorrheaTumor Markers, BiologicalVaccinesAdministration, IntranasalEstrogen Receptor betaNeoadjuvant Therapy